Digest Network Come funziona
Network
/
Società
NI
Non verificato

NImmune Biopharma

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaIndustriaSalute

9 comunicati stampa

Guarda tutti i comunicati
13/10/2026
Volontariato/Solidarietà/Non profit
Industria
Salute
Tecnica
Tecnologie Varie
Sanità
Farmaceutica
NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
14/09/2026
Eventi
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
NImmune Biopharma Announces Presentations at ACG 2026 Supporting Efficacy of Oral, Once-Daily NIM-1324 LANCL2 Medicine for Hard-to-Treat IBD
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
05/05/2026
Eventi
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
24/03/2026
Eventi
Finanza
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
17/02/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Leading the Next Wave of Innovative IBD Therapeutics Targeting Immunometabolism: Josep Bassaganya-Riera Launches Clinical Program and Business Venture to Develop NIM-1324 for Ulcerative Colitis and Crohn’s disease
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
06/05/2025
Eventi
Industria
Scienza
Sanità
Associazioni/Professionisti
Farmaceutica
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
23/10/2024
Mercato azionario
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
16/09/2024
Eventi
Web e Social Network
Salute
Scienza
Farmaceutica
Biotecnologia
NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company Symposium
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0
05/09/2024
Mercato del lavoro
Industria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines
Fonte
NImmune Biopharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0